View Older Stories View More Recent Stories

Nov 18, 2025 07:30AM InMed Announces Successful Completion of Pharmacokinetic Studies in Large Animal Model for Its Alzheimer's Disease Candidate INM-901
Nov 6, 2025 04:51PM InMed Reports First Quarter Fiscal 2026 Financial Results and Provides Business Update
Oct 16, 2025 08:32AM InMed Pharmaceuticals adds John Bathery to board of directors
Oct 16, 2025 08:30AM Inmed Pharmaceuticals Appoints Mr. John Bathery to Its Board of Directors
Oct 14, 2025 06:07AM InMed Pharmaceuticals appoints Neil Klompas to board of directors
Oct 9, 2025 08:32AM InMed Pharmaceuticals names Neil Klompas to board of directors
Oct 9, 2025 08:30AM InMed Pharmaceuticals Appoints Mr. Neil Klompas to It's Board of Directors
Sep 23, 2025 08:30AM InMed Pharmaceuticals Reports Full Year Fiscal 2025 Financial Results and Provides Business Update
Sep 5, 2025 09:33AM InMed to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
Aug 1, 2025 06:05AM InMed Pharmaceuticals Inc. (INM) Files for 3.9M Share Offering by Selling Stockholders
Jul 28, 2025 07:00AM InMed to Present INM-901 Data at Alzheimer's Association International Conference (AAIC) 2025
Jun 27, 2025 07:00AM InMed Pharmaceuticals Announces Closing of $5 Million Private Placement Priced At-the-Market under Nasdaq Rules
Jun 25, 2025 08:03AM InMed Pharmaceuticals Inc. (INM) Announces 1.95M Share Offering at $2.561/sh
Jun 25, 2025 08:00AM InMed Pharmaceuticals Announces $5 Million Private Placement Priced At-the-Market Under Nasdaq Rules
Jun 24, 2025 07:02AM InMed Pharmaceuticals (INM) Announces INM-901 Significantly Reduces Neuroinflammation in Alzheimer's Disease Ex Vivo Study
Jun 24, 2025 07:00AM InMed's INM-901 Significantly Reduces Neuroinflammation in Alzheimer's Disease Ex Vivo Study
Jun 13, 2025 04:30PM InMed Appoints CBIZ as New Auditor in Connection with CBIZ's Acquisition of Marcum's Attest Business, Provides Update on Special Meeting and Makes Modifications to Existing SEPA
May 13, 2025 06:46AM InMed Pharmaceuticals Inc. (INM) Misses Q3 EPS by 194c
May 12, 2025 06:00PM InMed Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update
Feb 13, 2025 04:08AM InMed Pharmaceuticals Inc. (inm) Misses Q2 EPS by 364c
Feb 13, 2025 04:05AM InMed Pharmaceuticals Inc. (inm) Misses Q2 EPS by 364c
Feb 12, 2025 06:54PM InMed Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update
Feb 3, 2025 07:33AM InMed Pharmaceuticals Inc. (INM) Announces INM-089 Intravitreal Formulation in the Treatment of Dry Age-Related Macular Degeneration
Feb 3, 2025 07:30AM InMed Announces INM-089 Intravitreal Formulation in the Treatment of Dry Age-Related Macular Degeneration
Jan 22, 2025 07:32AM InMed Pharmaceuticals Inc. (INM) Granted Patent for Novel Compounds
Jan 22, 2025 07:30AM InMed Pharmaceuticals Announces Granting of Patent for Novel Compounds
Jan 21, 2025 07:34AM InMed Pharmaceuticals' (INM) INM-901 Demonstrates Statistically Significant Reduction in Neuroinflammation in a Long-Term Preclinical Alzheimer's Disease Study
Jan 21, 2025 07:30AM InMed's INM-901 Demonstrates Statistically Significant Reduction in Neuroinflammation in a Long-Term Preclinical Alzheimer's Disease Study
Dec 23, 2024 05:18PM InMed Pharmaceuticals Inc. (INM) Files for 3M Share Offering by Selling Stockholders
Dec 18, 2024 08:00PM InMed Announces Results of 2024 Annual General Meeting
Dec 17, 2024 04:58PM InMed Pharmaceuticals (INM) Enters $10M Standby Equity Purchase Agreement
Dec 17, 2024 04:56PM InMed Enters Into Standby Equity Purchase Agreement
Nov 19, 2024 07:30AM InMed Announces Publication of Study on Anti-Inflammation by Modulation of Endocannabinoid System
Nov 14, 2024 09:14PM InMed Pharmaceuticals Inc. (INM) Reports Q1 Loss of $2.17
Nov 14, 2024 04:45PM InMed Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update
Nov 8, 2024 04:44PM InMed Announces Share Consolidation to Satisfy Nasdaq Listing Rules
Nov 5, 2024 08:32AM InMed Pharmaceuticals Inc. (INM) Granted Nasdaq Exception to Implement Share Consolidation
Nov 5, 2024 08:30AM InMed Pharmaceuticals Announces Decision by NASDAQ Hearings Panel to Grant Exception to Implement Share Consolidation to Satisfy NASDAQ Listing Rules
Oct 28, 2024 07:32AM InMed Pharmaceuticals Inc. (INM) Files Additional Patent Application for INM-901 in the Treatment of Neurodegenerative Conditions Including Alzheimer's Disease
Oct 28, 2024 07:30AM InMed Pharmaceuticals Files Additional Patent Application for INM-901 in the Treatment of Neurodegenerative Conditions Including Alzheimer's Disease
Oct 24, 2024 08:00AM InMed to Participate in Fierce Biotech Webinar on Neuroinflammation in Alzheimer's Disease
Oct 22, 2024 08:00AM InMed Appoints Dr. Barry Greenberg, Johns Hopkins University School of Medicine, to its Scientific Advisory Board
Sep 30, 2024 08:00AM InMed Pharmaceuticals Reports Full Year Fiscal 2024 Financial Results and Provides Business Update
Sep 20, 2024 04:32PM InMed (INM) Receives NASDAQ Delisting Notice
Sep 20, 2024 04:30PM InMed Receives NASDAQ Delisting Notice, and Confirms it has Filed an Appeal and Obtained a Panel Hearing Date
Aug 21, 2024 07:30AM InMed Pharmaceuticals Strengthens Patent Portfolio with Issuance of Three U.S. Patents
Aug 20, 2024 07:32AM InMed Pharmaceuticals (INM) Demonstrates INM-901 as an Oral Formulation Targeting Alzheimer's Disease
Aug 20, 2024 07:30AM InMed Pharmaceuticals Demonstrates INM-901 as an Oral Formulation Targeting Alzheimer's Disease
Jul 30, 2024 08:03AM InMed Pharmaceuticals Inc. (INM) Receives Favorable Behavioral Outcomes with INM-901
Jul 30, 2024 08:00AM InMed Pharmaceuticals Announces Favorable Behavioral Outcomes with INM-901 in Long-Term Preclinical Alzheimer's Disease Study, Confirming Previous Short-Term Pilot Study Data
View More Recent Stories View Older Stories